Financial Data and Key Metrics Changes - The company has used approximately $5.9 million for the first three quarters of the year and expects significant revenue in the fourth quarter to offset operating expenses [30][31] - The company aims to cover operating expenses through financings and anticipates a good fourth quarter [31][32] - The market value of the company's stock is currently undervalued compared to its significant equity holdings in companies like Exazyme and Heartbeat [32][33] Business Line Data and Key Metrics Changes - The company is focused on launching three to five companies per year to build a public venture portfolio, which is a shift from the historical rate of one company every 18 months [9][24] - The company has a deep pipeline of opportunities and believes that future launches will have a better probability of success than past ones [24][27] Market Data and Key Metrics Changes - The microcap market has been challenging, but the company believes it is on the verge of a resurgence due to increased demand for public companies with revenue and earnings [28][50] - There is a growing trend of companies seeking to go public as private equity and venture capital funding becomes less attractive [55][56] Company Strategy and Development Direction - The company aims to create a sustainable business model that can survive beyond its founders by scaling operations and launching more companies [9][24] - The focus is on curating high-potential companies and transforming them into investable public entities with significant growth potential [12][13] - The company is also exploring the potential of a spinout in the patent law sector, which could provide substantial value [34][64] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges in the microcap market but remains optimistic about future opportunities and the potential for public venture to thrive again [28][30] - The company is committed to improving communication with shareholders and enhancing investor relations to better convey its value proposition [68][70] Other Important Information - The company is preparing for the IPO of Buddha Juice and expects to close multiple deals in the near future, indicating a busy pipeline [27][40] - Management emphasizes the unique value proposition of their public venture platform, which differentiates them from traditional private equity and venture capital firms [16][39] Q&A Session Summary Question: When can shareholders expect to see a dividend? - The company prefers to wait until there is a developed market for the stock and broader ownership before considering dividends [42] Question: Will shareholders retain the same percentage of ownership as Exazyme raises funds? - Shareholders will experience dilution as companies raise more capital, but efforts will be made to minimize this [43] Question: What is the outlook for Heartbeat regarding FDA approval? - The company is optimistic about FDA approval and believes it will facilitate future fundraising efforts [46] Question: Why is the stock trading at a low price compared to the IPO? - The poor performance of the microcap market and concerns about the company's ability to select successful investments are contributing factors [48][49] Question: What makes the cost of being public more favorable for listings? - Companies that are profitable and growing in the microcap sector are trading at attractive valuations, making public listings more appealing [50][51] Question: Can you clarify the PatentVest spinout and its potential market value? - The spinout is expected to have substantial market value due to the disruption AI will bring to the legal sector, particularly in patent law [63][66]